References
- Eucrisa (crisaborole) [full prescribing information]. New York (NY): Pfizer, Inc; 2017.
- Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83:1583–1590.
- Eichenfield LF, Call RS, Forsha DW, et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J Am Acad Dermatol. 2017;77:641–649.
- Zane LT, Kircik L, Call R, et al. Crisaborole topical ointment, 2% in patients ages 2 to 17 years with atopic dermatitis: a phase 1b, open-label, maximal-use systemic exposure study. Pediatr Dermatol. 2016;33:380–387.
- Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4), in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73:37–49.
- AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis – Study Results. Study Results – ClinicalTrials.gov. 2017 [cited 2018 Mar 27]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01300052?term=crisaborole&cond=Psoriasis&rank =1§=X01256